Back

The effect of semaglutide on mortality and COVID-19-related deaths - a pre-specified analysis from the SELECT trial

30 August 2024 (09:33 - 09:45)
Organised by: Logo
Congress Presentation Part of: Clinical trial updates on the GLP-1 receptor agonist, semaglutide Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Benjamin Morgan Scirica

Brigham and Women's Hospital, Boston (United States of America)

7 More presentations in this session

Presentation thumbnail
Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials
Doctor M. Kosiborod (Kansas City, US)
Slides Video
Presentation thumbnail
Inflammation in obesity-related HFpEF: the STEP-HFpEF programme
Professor S. Verma (Toronto, CA)
Slides Video
Presentation thumbnail
STEP-HFpEF Program Echocardiography Substudy
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease
Doctor R. Pratley (Orlando, US)
Slides Video
Presentation thumbnail
Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials
Doctor M. Kosiborod (Kansas City, US)
Slides Video

Access the full session

Session thumbnail
Clinical trial updates on the GLP-1 receptor agonist, semaglutide
Video

The Event

Event poster

ESC Congress 2024

30 August 2024 09:33 CET
You may be interested in
thumbnail
Congress Presentation
Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial
31 August 2024
thumbnail
Congress Presentation
Association of COVID-19 and influenza vaccinations and cardiovascular drugs with hospitalisation and mortality in COVID-19 and Long COVID: 2-year follow-up of 17 million individuals in England
31 August 2024
thumbnail
Congress Session
HOT LINE 9
28 August 2023
thumbnail
Congress Presentation
Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the SELECT trial
14 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources